Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically confirmed malignant glioma

- Grade 3 or 4 disease

- In first, second, or third recurrence or relapse

- Multifocal disease allowed

PATIENT CHARACTERISTICS:

- Karnofsky performance status 70-100%

- Life expectancy ≥ 12 weeks

- Absolute neutrophil count > 1,500/mm^3

- Hemoglobin > 9 g/dL

- Platelet count > 100,000/mm^3

- Potassium normal*

- Total calcium (corrected) normal*

- Magnesium normal*

- Phosphorus normal*

- aspartate transaminase (AST) and alanine transaminase (ALT) < 2.5 times upper limit
of normal (ULN)

- Bilirubin < 1.5 times ULN

- Negative proteinuria by dipstick OR total urinary protein ≤ 500 mg with creatinine
clearance ≥ 50 mL/min by 24-hour urine collection

- Creatinine < 1.5 times ULN OR creatinine clearance > 50 mL/min

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No acute or chronic liver or renal disease

- left ventricular ejection fraction (LVEF) ≥ 45% by Multi Gated Acquisition Scan
(MUGA) or echocardiogram

- No complete left bundle branch block

- No obligate use of a cardiac pacemaker

- No congenital long QT syndrome

- No history of or current ventricular or atrial tachyarrhythmias

- No clinically significant resting bradycardia (i.e., heart rate < 50 beats/minute)

- No right bundle branch block with left anterior hemiblock (bifascicular block)

- No uncontrolled hypertension ≥ grade 2, history of labile hypertension, or history of
poor compliance with an antihypertensive regimen

- No concurrent unstable angina pectoris or angina pectoris within the past 3 months

- No congestive heart failure (CHF)

- No history of CHF or arrhythmias requiring concurrent digoxin or verapamil

- No acute myocardial infarction within the past 3 months

- No other impaired cardiac function or clinically significant cardiac disease

- No peripheral neuropathy ≥ grade 2

- No unresolved diarrhea ≥ grade 2

- No uncontrolled diabetes

- No active or uncontrolled infection requiring intravenous antibiotics

- No impaired gastrointestinal (GI) function or GI disease that may significantly alter
the absorption of vatalanib, hydroxyurea, and/or everolimus, including any of the
following:

- Ulcerative disease

- Uncontrolled nausea, vomiting, or diarrhea

- Malabsorption syndrome

- Small bowel resection

- No other concurrent severe and/or uncontrolled medical condition that would preclude
study participation or compliance

- No known HIV positivity

- No other primary malignancy that is clinically significant or requires active
intervention NOTE: *Supplement allowed

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- More than 2 weeks since prior tumor biopsy (4 weeks since prior surgical resection)

- Prior polifeprosan 20 with carmustine implant (Gliadel® wafer) allowed at discretion
of principal investigator

- Prior hydroxyurea allowed

- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and 1 week for
metronomic-dosed chemotherapy [e.g., daily etoposide hydrochloride or
cyclophosphamide]) and recovered

- More than 4 weeks since prior radiotherapy and recovered

- More than 2 weeks since prior immunotherapy and recovered

- More than 4 weeks since prior investigational drugs and recovered

- No prior platelet-derived growth factor- or vascular endothelial growth
factor-directed therapies

- More than 2 weeks since prior hematopoietic colony-stimulating factor (e.g.,
filgrastim [G-CSF] or sargramostim [Granulocyte-macrophage colony-stimulating factor
(GM-CSF)])

- Prior epoetin alfa allowed

- No concurrent warfarin